Healthcare -
Biotechnology - NASDAQ - US
$ 0.6454
21.8 %
$ 59.2 M
Market Cap
-0.44
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Verrica Pharmaceuticals Inc.
| Revenue | 7.57 M |
| Cost Of Revenue | 1.85 M |
| Gross Profit | 5.71 M |
| Operating Expenses | 71.6 M |
| Operating Income | -65.9 M |
| Other Expenses | 10.7 M |
| Net Income | -76.6 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 7.6 | 5.1 | 9.0 | 12.0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 1.9 | 0.7 | 0.7 | 0.5 | 0.2 | 0.3 | 20.3 K | 0 | 0 |
| Gross Profit | 5.7 | 4.4 | 8.3 | 11.5 | (0.2) | (0.3) | 20.3 K | 0 | 0 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 71.6 | 70.1 | 29.6 | 42.9 | 40.2 | 30.1 | 21.9 | 4.5 | 1.9 |
| Selling, General and Administrative Expenses | 58.8 | 47.3 | 17.4 | 27.0 | 24.5 | 14.6 | 9.1 | 0.7 | 0.2 |
| Research and Development Expenses | 11.8 | 20.3 | 12.2 | 15.9 | 15.7 | 15.4 | 12.8 | 3.7 | 1.7 |
| Operating Income | (65.9) | (65.8) | (21.3) | (30.9) | (40.2) | (30.1) | (21.9) | (4.5) | (1.9) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 9.4 | 4.0 | 2.2 | 4.3 | 3.0 | 0 | 0 | 2 K | 0 |
| Total Other Income | (10.7) | (1.2) | (3.2) | (4.2) | (2.5) | 1.9 | 1.2 | 2 K | 0 |
| Pre-Tax Income | (76.6) | (67.0) | (24.5) | (35.1) | (42.7) | (28.2) | (20.6) | (4.5) | (1.9) |
| NET INCOME | |||||||||
| Tax Provision | 0 | 0 | 3.2 | 3.8 | 2.8 | (0.3) | 1.2 | (4.5) | (1.9) |
| Net Income | (76.6) | (67.0) | (27.7) | (38.9) | (45.5) | (27.9) | (20.6) | (4.5) | (1.9) |
| EPS | 1.48 | 1.48 | 0.81 | 1.44 | 1.82 | 1.12 | 1.41 | 0.22 | 0.0959 |